Clarity Risk Tool Not Used at Local Hospitals, Despite AI Use in Mammograms
AI tools for breast cancer detection show promise, but a new FDA-approved risk assessment tool, Clarity, has significant limitations and is not currently used in Norfolk-Portsmouth-Newport News hospitals, although some local facilities are using AI in mammograms.
Norfolk Portsmouth Newport News, VA, October 22, 2026 —
A newly FDA-approved breast cancer risk assessment tool called Clarity is not currently used in hospitals in the Norfolk-Portsmouth-Newport News area, even as some local facilities use artificial intelligence in mammograms.
The available information describes Clarity as having significant limitations but does not specify what those limitations are. It also does not identify the tool’s developer, explain how it assesses risk, or provide details about its FDA approval. Those details are not available in the trend summary.
The distinction between the tool and other local AI use is important: Clarity is described as a risk assessment tool, while some area facilities are reported to use AI in mammograms. The information provided does not identify those facilities or explain what their mammography systems do.
The trend summary says AI tools for breast cancer detection show promise, but it does not provide study results, accuracy figures, or other evidence to quantify that promise. It also does not say whether local facilities plan to adopt Clarity or when that might happen.
As a result, the information establishes that Clarity is not currently in use at the area’s hospitals and that some facilities use AI with mammograms, but leaves key questions unanswered. The number of facilities involved, the specific systems in use, and the practical implications of Clarity’s stated limitations were not provided.
Story summarized from the original created by Gabrielle Harmon on www.wtkr.com, see more information here.
